A Phase 3b, Controlled, Open-Label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's Meningococcal ACWY Conjugate Vaccine (Menveo), Administered to Healthy Individuals 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination
收藏DataCite Commons2024-11-27 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00005038/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose/aim of this study is to assess the safety and antibody response to vaccination with a booster dose of Menveo given 4-6 years after primary MenACWY vaccination and to assess the safety and antibody response to a single dose of Menveo given to vaccine-naïve subjects
提供机构：
Vivli
创建时间：
2019-11-20
